William Blair Predicts Higher Earnings for Twist Bioscience

Twist Bioscience Co. (NASDAQ:TWST) – Equities researchers at William Blair upped their Q2 2025 EPS estimates for Twist Bioscience in a research note issued to investors on Tuesday, February 4th. William Blair analyst M. Larew now forecasts that the company will earn ($0.55) per share for the quarter, up from their prior estimate of ($0.57). The consensus estimate for Twist Bioscience’s current full-year earnings is ($2.27) per share. William Blair also issued estimates for Twist Bioscience’s Q3 2025 earnings at ($0.55) EPS, FY2025 earnings at ($2.07) EPS, Q1 2026 earnings at ($0.41) EPS, Q3 2026 earnings at ($0.39) EPS, Q4 2026 earnings at ($0.28) EPS and FY2026 earnings at ($1.49) EPS.

Several other equities research analysts have also issued reports on TWST. Scotiabank lifted their price objective on shares of Twist Bioscience from $54.00 to $62.00 and gave the company a “sector outperform” rating in a research note on Tuesday. Wolfe Research began coverage on Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 price target for the company. Leerink Partners increased their price objective on Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. JPMorgan Chase & Co. raised their price objective on Twist Bioscience from $35.00 to $40.00 and gave the company an “underweight” rating in a research note on Tuesday. Finally, Robert W. Baird increased their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $53.80.

Twist Bioscience Stock Up 0.1 %

NASDAQ TWST opened at $53.70 on Thursday. The company has a 50 day moving average price of $48.84 and a two-hundred day moving average price of $46.32. Twist Bioscience has a 12-month low of $27.41 and a 12-month high of $60.90. The stock has a market capitalization of $3.19 billion, a PE ratio of -14.92 and a beta of 1.87.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million for the quarter, compared to analyst estimates of $86.96 million. Twist Bioscience had a negative return on equity of 32.27% and a negative net margin of 66.69%. The business’s revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.75) EPS.

Insider Buying and Selling at Twist Bioscience

In related news, CEO Emily M. Leproust sold 5,200 shares of the company’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $49.35, for a total value of $256,620.00. Following the sale, the chief executive officer now owns 667,318 shares of the company’s stock, valued at $32,932,143.30. The trade was a 0.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CFO Adam Laponis sold 5,886 shares of Twist Bioscience stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $43.26, for a total value of $254,628.36. Following the sale, the chief financial officer now directly owns 110,096 shares in the company, valued at $4,762,752.96. The trade was a 5.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 59,002 shares of company stock valued at $2,851,681 in the last quarter. Corporate insiders own 3.01% of the company’s stock.

Institutional Trading of Twist Bioscience

A number of large investors have recently bought and sold shares of the stock. Thrivent Financial for Lutherans bought a new stake in Twist Bioscience during the 3rd quarter worth approximately $43,992,000. State Street Corp boosted its stake in Twist Bioscience by 19.9% in the third quarter. State Street Corp now owns 3,167,353 shares of the company’s stock worth $143,101,000 after purchasing an additional 526,028 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Twist Bioscience by 188.5% during the third quarter. Wellington Management Group LLP now owns 797,737 shares of the company’s stock worth $36,042,000 after purchasing an additional 521,272 shares during the last quarter. Jennison Associates LLC increased its stake in shares of Twist Bioscience by 80.2% in the fourth quarter. Jennison Associates LLC now owns 680,778 shares of the company’s stock valued at $31,636,000 after buying an additional 302,884 shares in the last quarter. Finally, ARK Investment Management LLC raised its holdings in shares of Twist Bioscience by 4.4% in the fourth quarter. ARK Investment Management LLC now owns 5,595,865 shares of the company’s stock valued at $260,040,000 after buying an additional 237,772 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.